NCT06200207Active, not recruitingPhase 3
Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Active, not recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 680
- Locations
- 631
- Primary Endpoint
- Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS)
Study Overview
Brief Summary
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 milligrams per liter (mg/L) at screening (visit 1)
- •Disease specific - cardiovascular:
- •N-terminal-pro-brain natriuretic peptide (NT-proBNP) greater than or equal to 225 picograms per milliliter (pg/mL) (375 pg/mL for participants with atrial fibrillation/flutter) at screening
- •Diagnosis of heart failure (New York heart association (NYHA) Class II-III)
- •Left ventricular ejection fraction (LVEF) greater than 40 percent documented by echocardiography within 12 months prior to or at screening (visit 1). The LVEF must be documented in medical records and the most recent measurement must be used to determine eligibility with no interim event signalling potential deterioration in ejection fraction (example myocardial infarction (MI) or heart failure (HF) hospitalisation)
- •Structural heart disease and/or functional heart disease documented by echocardiography within 12 months prior to or at screening (visit 1) showing at least one of the following:
- •Left atrial (LA) volume index greater than 34 milliliter per square meter (mL/m^2)
- •LA diameter greater than or equal to 3.8 centimeters (cm)
- •LA length greater than or equal to 5.0 cm
- •LA area greater than or equal to 20 square centimeters (cm^2)
- •LA volume greater than or equal to 55 milliliters (mL)
- •Intraventricular septal thickness greater than or equal to 1.1 cm
- •Posterior wall thickness greater than or equal to 1.1 cm
- •LV mass index greater than or equal to 115 grams per square meter (g/m^2) in men or greater than or equal to 95 g/m^2 in women
- •h) E/e' (mean septal and lateral) greater than or equal to 10 i) e' (mean septal and lateral) less than 9 centimeters per second (cm/s)
- •No heart failure hospitalisations or urgent heart failure visits between screening and randomisation
- •Able to perform the 6-minute walk test (6MWT) at screening with a minimum distance of 100 metres
- •Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score lesser than 80 at screening
Exclusion Criteria
- •Medical conditions - cardiovascular:
- •Myocardial infarction, stroke, unstable angina pectoris, transient ischaemic attack, or heart failure hospitalisation within 30 days prior to screening (visit 1)
- •Systolic blood pressure greater than or equal to 180 millimeters of mercury (mmHg) at screening (visit 1). If the systolic blood pressure is 160-179 mmHg, the patient should be receiving greater than or equal to 3 antihypertensive drugs
- •Heart rate above 110 or below 40 beats per minute as evaluated on the Electrocardiogram (ECG) performed at screening (visit 1)
- •Planned coronary, carotid or peripheral artery revascularisation known during the screening period (visit 1)
- •Planned cardiac device or atrial flutter/atrial fibrillation ablation procedure known during the screening period (visit 1)
- •Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2)
- •Heart failure due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, uncorrected more than moderate primary valve disease
- •Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including chronic obstructive pulmonary disease (COPD)
- •Any other condition judged by the investigator that could account for heart failure symptoms and signs (e.g., anaemia, hypothyroidism)
- •Medical conditions - infections/immunosuppression:
- •Clinical evidence of, or suspicion of, active infection at the discretion of the investigator
Arms & Interventions
Ziltivekimab
Active Comparator
Participants will receive ziltivekimab administered subcutaneously (s.c.) once-monthly and added to standard of care for 12 months.
Intervention: Ziltivekimab (Drug)
Placebo
Placebo Comparator
Participants will receive placebo matched to ziltivekimab administered s.c. once-monthly and added to standard of care for 12 months.
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS)
Time Frame: From randomisation (month 0) to end-of-treatment (month 12)
Measured as score (score on scale; range; 0-100). The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.
Secondary Outcomes
- Change in subscales of KCCQ (total symptom score, physical limitations score, social limitations score, and health-related quality of life)(From randomisation (month 0) to end-of-treatment (month 12))
- Participants improving 5 points or more in KCCQ-CSS (yes/no)(From randomisation (month 0) to end-of-treatment (month 12))
- Change in six-minute walk distance (6MWD)(From randomisation (month 0) to end-of-treatment (month 12))
- Change in N-terminal-pro-brain natriuretic peptide (NT-proBNP)(From randomisation (month 0) to end-of-treatment (month 12))
- Change in eGFR (CKD-EPI)(From randomisation (month 0) to end-of-treatment (month 12))
- Participant achieving threshold for clinically meaningful within-participant change in KCCQ CSS (yes/no)(From randomisation (month 0) to end-of-treatment (month 12))
- Change in high-sensitivity C-reactive protein (hs-CRP)(From randomisation (month 0) to end-of-treatment (month 12))
- Participant achieving threshold for clinically meaningful within-participant change in 6-minute walk distance (6MWD) (yes/no)(From randomisation (month 0) to end-of-treatment (month 12))
- Participants improving 10 points or more in KCCQ-CSS (yes/no)(From randomisation (month 0) to end-of-treatment (month 12))
- Participants experiencing improvement in New York heart association (NYHA) Class (yes/no)(From randomisation (month 0) to end-of-treatment (month 12))
Investigators
Study Sites (631)
Loading locations...
Similar Trials
Terminated
Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationHeart FailureNCT05636176Novo Nordisk A/S4,899
Completed
Phase 3
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationChronic Kidney DiseaseNCT05021835Novo Nordisk A/S6,385
Active, not recruiting
Phase 3
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackNCT06118281Novo Nordisk A/S10,000
Recruiting
Phase 3
Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammatiosystemische ontstekingenAtherosclerotic cardiovascular disease and chronic kidney disease1008220610038430NL-OMON54148ovo Nordisk120
Recruiting
Phase 3
Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammatioASCVD, CKD and systemic inflammationJPRN-jRCT2021210033Miyazaki Daisuke400